INDV stock icon

Indivior
INDV

$9.68
0.92%

Market Cap: $1.26B

 

About: Indivior PLC is a specialty and generic drug manufacturing company. The company is focused on the development, manufacture, and sale of prescription drugs for treatment of substance use disorders and other serious mental illnesses. Its products include, Sublocade, Perseris, Suboxone, Opvee among others. The vast majority of Indivior's revenue is generated in the United States, followed by United Kingdom and the rest of the world.

Employees: 1,164

0
Funds holding %
of 6,710 funds
0
Analysts bullish %
of 3 analysts

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

33% more first-time investments, than exits

New positions opened: 20 | Existing positions closed: 15

5% more funds holding

Funds holding: 94 [Q1] → 99 (+5) [Q2]

9% more call options, than puts

Call options by funds: $8.18M | Put options by funds: $7.51M

0.33% more ownership

Funds ownership: 48.02% [Q1] → 48.34% (+0.33%) [Q2]

0% more funds holding in top 10

Funds holding in top 10: 4 [Q1] → 4 (+0) [Q2]

10% less repeat investments, than reductions

Existing positions increased: 27 | Existing positions reduced: 30

64% less capital invested

Capital invested by funds: $3.36B [Q1] → $1.22B (-$2.14B) [Q2]

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$22
127%
upside
Avg. target
$23
134%
upside
High target
$24
148%
upside

3 analyst ratings

positive
100%
neutral
0%
negative
0%
Piper Sandler
David Amsellem
66% 1-year accuracy
23 / 35 met price target
127%upside
$22
Overweight
Reiterated
13 Sept 2024
Piper Sandler
David Amsellem
66% 1-year accuracy
23 / 35 met price target
127%upside
$22
Overweight
Initiated
23 Jul 2024
Craig-Hallum
Chase Knickerbocker
39% 1-year accuracy
7 / 18 met price target
148%upside
$24
Buy
Maintained
10 Jul 2024

Financial journalist opinion

Based on 265 articles about INDV published over the past 30 days